{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:19:09Z","timestamp":1770779949698,"version":"3.50.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semnephrol.2023.151340","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T08:25:19Z","timestamp":1681979119000},"page":"151340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Glomerular Filtration Rate Measurement and Chemotherapy Dosing"],"prefix":"10.1016","volume":"42","author":[{"given":"Mitchell H.","family":"Rosner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeta","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.semnephrol.2023.151340_bib0001","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist."},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151340_bib0002","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/annonc\/mdu129","article-title":"Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort","volume":"25","author":"Cathomas","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semnephrol.2023.151340_bib0003","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.ajkd.2005.08.038","article-title":"Renal function testing","volume":"47","author":"Rosner","year":"2006","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.625417","article-title":"Serum creatinine as a potential biomarker of skeletal muscle atrophy in non-small cell lung cancer patients","volume":"12","author":"das Neves","year":"2021","journal-title":"Front Physiol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000091","article-title":"Renal insufficiency and cancer treatments","volume":"1","author":"Launay-Vacher","year":"2016","journal-title":"ESMO Open."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0006","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br J Cancer."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0007","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10549-008-0131-1","article-title":"Renal Insufficiency and Anticancer Medications (IRMA) study group: prevalence of renal insufficiency in breast cancer patients and related pharmacological issues","volume":"124","author":"Launay-Vacher","year":"2010","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00408-008-9123-5","article-title":"Renal Insufficiency Anticancer Medications (IRMA) Study Group. Lung cancer and renal insufficiency: prevalence and anticancer drug issues","volume":"187","author":"Launay-Vacher","year":"2009","journal-title":"Lung."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0009","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.3816\/CGC.2009.n.029","article-title":"Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Drug management of prostate cancer: prevalence and consequences of renal insufficiency","volume":"7","author":"Launay-Vacher","year":"2009","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0010","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency Anticancer Medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","article-title":"Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function","volume":"21","author":"Kintzel","year":"1995","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0012","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0013","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2014.59.7302","article-title":"Effect of renal dysfunction on toxicity in three decades of cancer therapy evaluation program-sponsored single-agent phase I studies","volume":"34","author":"Beumer","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0014","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2008.09.012","article-title":"Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study","volume":"70","author":"Launay-Vacher","year":"2009","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0015","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/14740338.2018.1477937","article-title":"Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities","volume":"17","author":"Gonzalez","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0016","doi-asserted-by":"crossref","first-page":"141","DOI":"10.34067\/KID.0000952019","article-title":"GFR measurements and chemotherapy dosing in patients with kidney disease and cancer","volume":"1","author":"McMahon","year":"2020","journal-title":"Kidney360."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0017","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00432-005-0679-7","article-title":"Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge","volume":"131","author":"Holweger","year":"2005","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102139","article-title":"Drug dosing in cancer patients with decreased kidney function: a practical approach","volume":"93","author":"Sprangers","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151340_bib0019","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.ajkd.2017.10.005","article-title":"Improving carboplatin dosing based on eGFR","volume":"71","author":"Beumer","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1200\/JCO.2015.62.6341","article-title":"Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: Alliance A171201, an ancillary study of CALGB\/CTSU 49907","volume":"34","author":"Lichtman","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0021","first-page":"1043","article-title":"Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study","volume":"23","author":"Chen","year":"2015","journal-title":"Support Care Cancer."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0022","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0091270009347868","article-title":"Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function","volume":"50","author":"Khosravan","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0023","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2407-10-50","article-title":"Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel cisplatin chemotherapy: a prospective study","volume":"10","author":"Arrieta","year":"2010","journal-title":"BMC Cancer."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0024","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0006-2952(82)90177-0","article-title":"Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin","volume":"31","author":"Bowmer","year":"1982","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0025","first-page":"273","article-title":"Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines","volume":"10","author":"Paglialunga","year":"2017","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","article-title":"Creatinine: from physiology to clinical application","volume":"72","author":"Kashani","year":"2020","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0027","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0028","first-page":"63","article-title":"Cystatin C\u2013properties and use as diagnostic marker","volume":"35","author":"Grubb","year":"2000","journal-title":"Adv Clin Chem."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0029","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0030","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0031","article-title":"Correlation of serum cystatin C with glomerular filtration rate in patients receiving platinum-based chemotherapy","volume":"2016","author":"Cavalcanti","year":"2016","journal-title":"Anal Cell Pathol (Amst)."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0032","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.plabm.2017.05.005","article-title":"Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients","volume":"8","author":"Jones","year":"2017","journal-title":"Pract Lab Med."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0033","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-018-3762-x","article-title":"The value of serum cystatin C in early evaluation of renal insufficiency in patients undergoing chemotherapy: a systematic review and meta-analysis","volume":"83","author":"He","year":"2019","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0034","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.147.3659.753","article-title":"Micropuncture study of inulin absorption in the rat kidney","volume":"147","author":"Gutman","year":"1965","journal-title":"Science."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00440953","article-title":"Comparative assessment of techniques for estimation of glomerular filtration rate with 99mTc-DTPA","volume":"11","author":"Fawdry","year":"1985","journal-title":"Eur J Nucl Med."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0036","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s003300100864","article-title":"Contrast media as markers of GFR","volume":"12","author":"Frennby","year":"2002","journal-title":"Eur Radiol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0037","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2215\/CJN.11721018","article-title":"Estimation of kidney function in oncology: Implications for anticancer drug selection and dosing","volume":"14","author":"Casal","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0038","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2020.03.026","article-title":"How to determine kidney function in cancer patients?","volume":"132","author":"Sprangers","year":"2020","journal-title":"Eur J Cancer."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151340_bib0039","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.mnh.0000444813.72626.88","article-title":"Estimating and measuring glomerular filtration rate: methods of measurements and markers for estimation","volume":"23","author":"Lamb","year":"2014","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0040","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","article-title":"Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer","volume":"10","author":"Jodrell","year":"1992","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0041","unstructured":"eviQ Consensus Group. International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction. Public comment draft April 2022. https:\/\/www.eviq.org.au\/pages\/international-consensus-guideline-for-anticancer-d. Accessed April 17, 2023."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151340_bib0042","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1078155220978446","article-title":"Accurate determination of glomerular filtration rate in adults for carboplatin dosing: moving beyond Cockcroft and Gault","volume":"27","author":"Tsang","year":"2021","journal-title":"J Oncol Pharm Pract."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151340_bib0043","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt.729","article-title":"Assessment of glomerular filtration rate in health and disease: a state of the art review","volume":"102","author":"Levey","year":"2017","journal-title":"Clin Pharmacol Ther."},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151340_bib0044","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151340_bib0045","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"32","author":"Delgado","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1016\/j.semnephrol.2023.151340_bib0046","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151340_bib0047","doi-asserted-by":"crossref","first-page":"P1333","DOI":"10.1016\/S1470-2045(21)00377-6","article-title":"Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants","volume":"22","author":"Casal","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0048","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1200\/JCO.2012.44.2863","article-title":"Body-surface area-based chemotherapy dosing: appropriate in the 21st century?","volume":"30","author":"Beumer","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0049","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejca.2013.12.021","article-title":"Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma","volume":"50","author":"Shepherd","year":"2014","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrclinonc.2013.108","article-title":"Chemotherapy dosing in overweight and obese patients with cancer","volume":"10","author":"Lyman","year":"2013","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0051","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfh983","article-title":"Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example","volume":"20","author":"Delanaye","year":"2005","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0052","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/jcla.21513","article-title":"Risk of overestimation of kidney function using GFR-estimating equations in patients with low inulin clearance","volume":"26","author":"Nakata","year":"2012","journal-title":"J Clin Lab Anal."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0053","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.ajkd.2010.06.005","article-title":"Obesity, glomerular hyperfiltration, and the surface area correction","volume":"56","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0054","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1681\/ASN.2009020171","article-title":"Measured GFR as a confirmatory test for estimated GFR","volume":"20","author":"Stevens","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0055","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S0272-6386(00)70052-7","article-title":"Glomerular filtration rate in severely overweight normotensive humans","volume":"35","author":"Anastasio","year":"2000","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0056","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jcla.21648","article-title":"Indexing glomerular filtration rate to body surface area: clinical consequences","volume":"28","author":"Redal-Baigorri","year":"2014","journal-title":"J Clin Lab Anal."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0057","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","article-title":"Body surface area in normal-weight, overweight, and obese adults. A comparison study","volume":"55","author":"Verbraecken","year":"2006","journal-title":"Metabolism."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0058","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1475-097X.2006.00718.x","article-title":"The origin of the 1 x 73-m2 body surface area normalization: problems and implications","volume":"27","author":"Heaf","year":"2007","journal-title":"Clin Physiol Funct Imaging."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0059","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","article-title":"International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency","volume":"43","author":"Lichtman","year":"2007","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0060","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/ndt\/gft006","article-title":"Con: Should we abandon the use of the MDRD equation in favour of the CKD-EPI equation?","volume":"28","author":"Delanaye","year":"2013","journal-title":"Nephrol Dial Transplant."},{"issue":"24","key":"10.1016\/j.semnephrol.2023.151340_bib0061","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-20-4555","article-title":"Precision dosing of targeted therapies is ready for prime time","volume":"27","author":"Groenland","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2023.151340_bib0062","doi-asserted-by":"crossref","first-page":"F1048","DOI":"10.1152\/ajprenal.00691.2009","article-title":"Rapid diagnosis and quantification of acute kidney injury using fluorescent ratiometric determination of glomerular filtration rate in the rat","volume":"299","author":"Wang","year":"2010","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0063","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2011.294","article-title":"A portable fiberoptic ratiometric fluorescence analyzer provides rapid point-of-care determination of glomerular filtration rate in large animals","volume":"81","author":"Wang","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2023.151340_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104417","article-title":"Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB102, a novel fluorescent tracer agent for measurement of glomerular filtration rate","volume":"107","author":"Dorshow","year":"2019","journal-title":"Regul Toxicol Pharmacol."}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:40:32Z","timestamp":1759448432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0270929523000505"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151340","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glomerular Filtration Rate Measurement and Chemotherapy Dosing","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151340"}}